

I hereby certify that this correspondence is being filed via  
EFS-Web with the United States Patent and Trademark Office  
on June 7, 2007

PATENT  
Attorney Docket No.: 021819-000130US  
Client Reference No.: JUV2879.54-3

TOWNSEND and TOWNSEND and CREW LLP

By: Timothy S. Parker  
Timothy S. Parker

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Steven W. Dow, et al.

Application No.: 10/780,114

Filed: February 17, 2004

For: SYSTEMIC IMMUNE  
ACTIVATION METHOD USING  
NUCLEIC ACID-LIPID COMPLEXES

Customer No. 20350

Confirmation No.: 8036

Examiner: A. Wehbe

Art Unit: 1633

SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT UNDER  
37 CFR §1.97 and §1.98

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Karen B. Dow  
Reg. No. 29,684

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 858-350-6100  
Fax: 415-576-0300  
KBD:tsp

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/780,114
				Filing Date	February 17, 2004
				First Named Inventor	Dow, Steven W.
				Art Unit	1633
				Examiner Name	A. Wehbe
Sheet	1	of	1	Attorney Docket Number	021819-000130US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BA	AUF, Gregor, et al. "Implication of Macrophages in Tumor Rejection Induced by CpG-oligodeoxynucleotides Without Antigen", <i>Clinical Cancer Research</i> (2001) 7:3540-3543	<input type="checkbox"/>
	BB	VOLLMER, Jörg, et al. "Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation", <i>Immunology</i> (2004) 113:212-223	<input type="checkbox"/>
	BC		<input type="checkbox"/>
	BD		<input type="checkbox"/>
	BE		<input type="checkbox"/>
	BF		<input type="checkbox"/>
	BG		<input type="checkbox"/>
	BH		<input type="checkbox"/>
	BI		<input type="checkbox"/>
	BJ		<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.